116 related articles for article (PubMed ID: 26904994)
1. Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.
Li MX; Bi XY; Zhao H; Huang Z; Han Y; Zhao DB; Zhao JJ; Cai JQ
Chin Med J (Engl); 2016 Mar; 129(5):586-93. PubMed ID: 26904994
[TBL] [Abstract][Full Text] [Related]
2. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
[TBL] [Abstract][Full Text] [Related]
3. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
Yang Y; Luo X; Yang N; Feng R; Xian L
PLoS One; 2014; 9(11):e111651. PubMed ID: 25375151
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.
Wei KK; Jiang L; Wei YY; Wang YF; Qian XK; Dai Q; Guan QL
Tumour Biol; 2014 Sep; 35(9):8721-31. PubMed ID: 24870596
[TBL] [Abstract][Full Text] [Related]
6. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
Gao Y; Liu D
Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
[TBL] [Abstract][Full Text] [Related]
7. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis.
Huang X; Gao P; Song Y; Sun J; Chen X; Zhao J; Liu J; Xu H; Wang Z
BMC Cancer; 2014 Dec; 14():976. PubMed ID: 25519477
[TBL] [Abstract][Full Text] [Related]
8. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
9. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
Azuma K; Komohara Y; Sasada T; Terazaki Y; Ikeda J; Hoshino T; Itoh K; Yamada A; Aizawa H
Cancer Sci; 2007 Sep; 98(9):1336-43. PubMed ID: 17640298
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ
Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
Li S; Wu J; Chen Y; Tang W; Peng Q; Deng Y; Xie L; Wang J; Huang S; Li R; Qin X; Zhao J
Anticancer Drugs; 2014 Jan; 25(1):106-14. PubMed ID: 24025563
[TBL] [Abstract][Full Text] [Related]
12. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.
Deng Q; Yang H; Lin Y; Qiu Y; Gu X; He P; Zhao M; Wang H; Xu Y; Lin Y; Jiang J; He J; Zhou JX
Int J Clin Exp Pathol; 2014; 7(12):8312-21. PubMed ID: 25674197
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis.
Yao A; Wang Y; Peng X; Ye R; Wang Q; Qi Y; Zhou F
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2107-17. PubMed ID: 24994039
[TBL] [Abstract][Full Text] [Related]
17. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
[TBL] [Abstract][Full Text] [Related]
18. Evidence for an Association of ERCC1 Expression and Mismatch Repair Status with Overall Survival in Colorectal Cancer Patients.
Li P; Xiao ZT; Braciak TA; Ou QJ; Chen G; Oduncu FS
Oncol Res Treat; 2017; 40(11):702-706. PubMed ID: 29065415
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma.
Kawabata Y; Nishi T; Kidani A; Tajima Y
Pancreas; 2015 Aug; 44(6):937-44. PubMed ID: 25906447
[TBL] [Abstract][Full Text] [Related]
20. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
Doll CM; Aquino-Parsons C; Pintilie M; Klimowicz AC; Petrillo SK; Milosevic M; Craighead PS; Clarke B; Lees-Miller SP; Fyles AW; Magliocco AM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):721-7. PubMed ID: 22836058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
